



29 August 2022

ASX ANNOUNCEMENT

APPENDIX 4E – Financial Year Ended 30 June 2022

ImpediMed Limited (ASX:IPD) today released its Appendix 4E – Preliminary Final Report for the financial year ended 30 June 2022 (FY'22).

Approved for release by the Board of ImpediMed Limited.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T : +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

ImpediMed Limited - Appendix 4E
ABN 65 089 705 144
Preliminary final report

- 1** Current Financial Period Ended: 30 June 2022
Previous Corresponding Reporting Period: 30 June 2021

The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2022 ("2022 Annual Report") and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules. Certain prior year amounts have been reclassified for consistency with the current reporting period presentation.

2 Results for announcement to the market

	Current reporting period \$000	Previous corresponding period \$000
2.1 Revenue from ordinary activities	\$ 10,566	\$ 8,409
Increase in revenue (\$000):		\$ 2,157
Percentage increase:		26%
Note: Revenue related to goods and services for the year ended 30 June 2022 was \$10.6 million (2021 \$8.4 million). Within the Medical Segment, the SOZO Core Business revenue was \$6.6 million (2021: \$5.8 million), SOZO Clinical Business was \$3.3 million (2021: \$1.9) and Legacy Revenue was \$0.6 million (2021: \$0.7 million).		
2.2 (Loss) from ordinary activities after tax attributable to members	(19,874)	(20,706)
Decrease in loss from ordinary activities after tax attributable to members (\$000):		\$ 832
Percentage decrease:		4%
Note: Refer to the Directors' Report for a detailed analysis.		
2.3 Net (loss) for the period attributable to members	(19,874)	(20,706)
Decrease in net loss for the period attributable to members (\$000):		\$ 832
Percentage decrease:		4%
Note: Refer to 2.2 above and to the Directors' Report in the 2022 Annual Report.		

3 Dividends

3.1 Dividends Nil

There were no dividends declared and paid during the reporting period on ordinary shares.
There were no dividends proposed and not yet recognised as a liability during the reporting period.

3.2 Dividend Record Date Not applicable

4 Financial Statements		
4.1 Statement of comprehensive income Refer to the Consolidated Statement of Comprehensive Income in the 2022 Annual Report.		
4.2 Statement of financial position Refer to the Consolidated Balance Sheet in the 2022 Annual Report.		
4.3 Statement of cash flows Refer to the Consolidated Cash Flow Statement in the 2022 Annual Report.		
4.4 Statement of retained earnings Refer to the Consolidated Statement of Changes in Equity in the 2022 Annual Report for movements in retained earnings.		
5 Net tangible assets per security		
	Current reporting period	Previous corresponding period
5.1 Net tangible assets (\$000)	39,678	18,062
Issued share capital at reporting date (\$000)	307,557	267,268
	Current reporting period	Previous corresponding period
Number of shares on issue at reporting date	1,777,967,235	1,491,678,538
Net tangible assets per security	\$ 0.02	\$ 0.01
6 Earnings per security (EPS)		
	Current reporting period	Previous corresponding period
6.1 Weighted average number of ordinary shares (excluding reserved shares) for basic earnings per share (EPS)	1,678,954,154	1,202,320,326
(Loss) per share from continued operations		
Basic EPS	\$ (0.01)	\$ (0.02)
(Loss) per share from profit attributable to ordinary shares		
Basic EPS	\$ (0.01)	\$ (0.02)
Diluted earnings per share has been determined to be the same as basic earnings per share as the actual calculation is anti-dilutive for both periods presented.		
Refer to <i>Note 2 - Earnings per Share</i> in the 2022 Annual Report for additional information pertaining to EPS for the current reporting period.		
7 Acquisitions and divestments Not applicable.		
8 Foreign entities Not applicable.		
9 Associates and joint ventures Not applicable.		
10 Commentary on results for the financial year Refer to the 2022 Annual Report for the year ended 30 June 2022.		
11 Results of segments Refer to <i>Note 4 - Segment Reporting</i> in the 2022 Annual Report for additional information pertaining to segment results for the current reporting period.		
12 Audited Report The report is based on audited accounts which are not subject to dispute, modification, or qualification.		